245 related articles for article (PubMed ID: 37567170)
1. Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y; Katsnelson L; Gritsenko MA; Hu Y; Reva B; Hong R; Wang YT; Kolodziejczak I; Lu RJ; Tsai CF; Bu W; Liu W; Guo X; An E; Arend RC; Bavarva J; Chen L; Chu RK; Czekański A; Davoli T; Demicco EG; DeLair D; Devereaux K; Dhanasekaran SM; Dottino P; Dover B; Fillmore TL; Foxall M; Hermann CE; Hiltke T; Hostetter G; Jędryka M; Jewell SD; Johnson I; Kahn AG; Ku AT; Kumar-Sinha C; Kurzawa P; Lazar AJ; Lazcano R; Lei JT; Li Y; Liao Y; Lih TM; Lin TT; Martignetti JA; Masand RP; Matkowski R; McKerrow W; Mesri M; Monroe ME; Moon J; Moore RJ; Nestor MD; Newton C; Omelchenko T; Omenn GS; Payne SH; Petyuk VA; Robles AI; Rodriguez H; Ruggles KV; Rykunov D; Savage SR; Schepmoes AA; Shi T; Shi Z; Tan J; Taylor M; Thiagarajan M; Wang JM; Weitz KK; Wen B; Williams CM; Wu Y; Wyczalkowski MA; Yi X; Zhang X; Zhao R; Mutch D; Chinnaiyan AM; Smith RD; Nesvizhskii AI; Wang P; Wiznerowicz M; Ding L; Mani DR; Zhang H; Anderson ML; Rodland KD; Zhang B; Liu T; Fenyö D;
Cancer Cell; 2023 Sep; 41(9):1586-1605.e15. PubMed ID: 37567170
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
3. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
[TBL] [Abstract][Full Text] [Related]
4. Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R.
Zhang Y; Li MX; Wang H; Zeng Z; Li XM
Asian Pac J Cancer Prev; 2015; 16(1):221-5. PubMed ID: 25640355
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway.
Sun X; Xing G; Zhang C; Lu K; Wang Y; He X
Cell Biochem Funct; 2020 Mar; 38(2):141-148. PubMed ID: 31967350
[TBL] [Abstract][Full Text] [Related]
6. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomic Characterization of Endometrial Carcinoma.
Dou Y; Kawaler EA; Cui Zhou D; Gritsenko MA; Huang C; Blumenberg L; Karpova A; Petyuk VA; Savage SR; Satpathy S; Liu W; Wu Y; Tsai CF; Wen B; Li Z; Cao S; Moon J; Shi Z; Cornwell M; Wyczalkowski MA; Chu RK; Vasaikar S; Zhou H; Gao Q; Moore RJ; Li K; Sethuraman S; Monroe ME; Zhao R; Heiman D; Krug K; Clauser K; Kothadia R; Maruvka Y; Pico AR; Oliphant AE; Hoskins EL; Pugh SL; Beecroft SJI; Adams DW; Jarman JC; Kong A; Chang HY; Reva B; Liao Y; Rykunov D; Colaprico A; Chen XS; Czekański A; Jędryka M; Matkowski R; Wiznerowicz M; Hiltke T; Boja E; Kinsinger CR; Mesri M; Robles AI; Rodriguez H; Mutch D; Fuh K; Ellis MJ; DeLair D; Thiagarajan M; Mani DR; Getz G; Noble M; Nesvizhskii AI; Wang P; Anderson ML; Levine DA; Smith RD; Payne SH; Ruggles KV; Rodland KD; Ding L; Zhang B; Liu T; Fenyö D;
Cell; 2020 Feb; 180(4):729-748.e26. PubMed ID: 32059776
[TBL] [Abstract][Full Text] [Related]
8. Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling.
Huang X; Zhong R; He X; Deng Q; Peng X; Li J; Luo X
IUBMB Life; 2019 Feb; 71(2):223-234. PubMed ID: 30452118
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.
Chan DW; Mak CS; Leung TH; Chan KK; Ngan HY
Oncotarget; 2012 Dec; 3(12):1546-56. PubMed ID: 23295859
[TBL] [Abstract][Full Text] [Related]
11. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
[TBL] [Abstract][Full Text] [Related]
12. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
[TBL] [Abstract][Full Text] [Related]
13. Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway.
Chen H; Wang Y; Xue F
Oncol Rep; 2013 Feb; 29(2):507-14. PubMed ID: 23135473
[TBL] [Abstract][Full Text] [Related]
14. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Myers AP; Filiaci VL; Zhang Y; Pearl M; Behbakht K; Makker V; Hanjani P; Zweizig S; Burke JJ; Downey G; Leslie KK; Van Hummelen P; Birrer MJ; Fleming GF
Gynecol Oncol; 2016 Apr; 141(1):43-8. PubMed ID: 27016228
[TBL] [Abstract][Full Text] [Related]
16. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
17. Endometrial Carcinoma: Specific Targeted Pathways.
Eritja N; Yeramian A; Chen BJ; Llobet-Navas D; Ortega E; Colas E; Abal M; Dolcet X; Reventos J; Matias-Guiu X
Adv Exp Med Biol; 2017; 943():149-207. PubMed ID: 27910068
[TBL] [Abstract][Full Text] [Related]
18. Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism.
Conza D; Mirra P; Calì G; Insabato L; Fiory F; Beguinot F; Ulianich L
Cells; 2021 Apr; 10(5):. PubMed ID: 33946426
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway.
Qiang P; Shao Y; Sun YP; Zhang J; Chen LJ
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1778-1785. PubMed ID: 30840303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
